search
Back to results

LLIN Evaluation in Uganda Project (LLINEUP3)

Primary Purpose

Malaria

Status
Not yet recruiting
Phase
Not Applicable
Locations
Uganda
Study Type
Interventional
Intervention
long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)
long lasting insecticidal nets with PBO-pyrethroid (PermaNet)
Social Behavior Change Communication
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Malaria focused on measuring long lasting insecticidal nets with chlorfenapyr-pyrethroid, long lasting insecticidal nets with with PBO-pyrethroid

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Household Survey Inclusion Criteria: At least one adult aged 18 years or older present Adult is a usual resident who slept in the sampled household on the night before the survey Agreement of the adult resident to provide informed consent for the household and entomology survey Exclusion Criteria: Dwelling destroyed or not found Household vacant No adult resident home on more than 3 occasions Clinical Survey Inclusion Criteria: Usual resident who was present in the sampled household on the night before the survey Agreement of adult or parent/guardian (of children) to provide informed consent Agreement of child aged 8 years or older to provide assent Exclusion Criteria: 1. Resident not home on day of survey

Sites / Locations

  • Infectious Diseases Research Collaboration

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PermaNet Dual

PermaNet 3.0

Arm Description

long lasting insecticidal nets with chlorfenapyr-pyrethroid

long lasting insecticidal nets with PBO-pyrethroid

Outcomes

Primary Outcome Measures

Number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the target area
malaria incidence: number of cases divided by the total population of the target area

Secondary Outcome Measures

Prevalence of parasitaemia
Proportion of blood smears positive for parasites by microscopy in individuals of all ages at the time of cross-sectional surveys
Prevalence of anemia
Proportion of children aged 2-4 years with haemoglobin < 11 g/dL at the time of cross-sectional surveys
Proportion of households that owned at least one LLIN
Proportion of households with at least one LLIN at the time of cross-sectional surveys
Proportion of households that owned at least one LLIN for every two occupants
Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys
Proportion of household residents who slept under an LLIN the previous night
Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys
Number of female anopheles mosquitoes collected per household at the time of cross-sectional surveys
Vector density

Full Information

First Posted
July 10, 2023
Last Updated
July 18, 2023
Sponsor
University of California, San Francisco
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Research Collaboration, Uganda, Ministry of Health, Uganda, Against Malaria Foundation, Liverpool School of Tropical Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05950191
Brief Title
LLIN Evaluation in Uganda Project (LLINEUP3)
Official Title
LLIN Evaluation in Uganda Project (LLINEUP3): Impact of Long-lasting Insecticidal Nets (LLINs) Treated With Chlorfenapyr Plus Pyrethroid vs LLINs Treated With Piperonyl Butoxide Plus Pyrethroid on Malaria Incidence in Uganda: a Cluster-randomised Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 1, 2023 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), Infectious Diseases Research Collaboration, Uganda, Ministry of Health, Uganda, Against Malaria Foundation, Liverpool School of Tropical Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In Uganda, the National Malaria Control Division (NMCD) and implementing partners are planning to deliver long-lasting insecticidal nets (LLINs) nationwide, through a mass distribution campaign in 2023. LLINs will be distributed free-of-charge to all Ugandan households, aiming to achieve universal coverage. LLINs treated with a pyrethroid insecticide plus chlorfenapyr (PermaNet Dual, Vestergaard) and LLINs treated with a pyrethroid insecticide plus PBO (PermaNet 3.0, Vestergaard) will be distributed as part of this distribution campaign, presenting an opportunity to rigorously evaluate and compare these two LLINs at scale across Uganda. In collaboration with the MOH, this cluster-randomised trial will compare the impact of LLINs combining chlorfenapyr with a pyrethroid to LLINs combining PBO with a pyrethroid into Uganda's 2023 LLIN distribution campaign, as was done successfully at the time of the last LLIN distribution campaign conducted in 2020-21. A major strength of this trial is the use of malaria incidence as the primary outcome measure. Incidence of malaria, defined as the number of symptomatic cases of malaria occurring in a population at risk over time, is the gold standard for assessing malaria burden. However, cluster-randomised trials using malaria incidence as the primary outcome typically involve study cohorts and are very expensive and logistically challenging. The novel approach for measuring malaria incidence is to utilize data collected routinely at health facilities. By defining target areas around health facilities and collecting data on the location of residence of patients diagnosed with malaria, this study will be able to generate longitudinal measures of malaria incidence at an unprecedented scale across Uganda as done in the LLINEUP2 trial (NCT04566510). These results will inform policies and programmes for malaria and potentially provide evidence to support widescale deployment of dual AI chlorfenapyr-pyrethroid LLINs. This study, the first evaluating PermaNet Dual LLINs, will also provide evidence for a second in class chlorfenapyr net, a potential tool to be added to the malaria control tool kit.
Detailed Description
This is a cluster-randomised trial to evaluate the impact of long-lasting insecticidal nets (LLINs) distributed in Uganda through the 2023 national universal coverage campaign. A cluster has been defined as the target area surrounding an MRC. A total of 24 clusters will be included in the study, covering 20 moderate-high malaria burden districts in Uganda. Clusters have been randomised in a 1:1 ratio to receive one of two types of LLINs: (1) chlorfenapyr-pyrethroid LLINs (PermaNet Dual, n=12) or (2) PBO-pyrethroid LLINs (PermaNet 3.0, n=12). The intervention, including delivery of the LLINs and social and behaviour change communication (SBCC), will be led by the Ugandan NMCD and other stakeholders. Currently, LLINs are scheduled to be distributed in the study areas during waves 5 and 6 from September to October 2023 as part of the national LLIN distribution campaign. The evaluation of the intervention will include: 1) health facility surveillance at the participating MRCs to generate continuous estimates of malaria incidence for each MRC target area; 2) cross-sectional community surveys at 12- and 24-months post-LLIN distribution to gather information on parasite prevalence, anaemia prevalence, net ownership, coverage, and use, 3) entomology surveys at 12 and 24 months to gather information on vector density. The primary outcome of the trial will be malaria incidence as estimated using the health facility surveillance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria
Keywords
long lasting insecticidal nets with chlorfenapyr-pyrethroid, long lasting insecticidal nets with with PBO-pyrethroid

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Cluster-randomised trial to evaluate the impact of LLINs distributed in Uganda through the 2023 national universal coverage campaign. A cluster has been defined as the target area surrounding an MRC. A total of 24 clusters will be included in the study, covering 20 moderate-high malaria burden districts in Uganda. Clusters have been randomised in a 1:1 ratio to receive one of two types of LLINs: (1) chlorfenapyr-pyrethroid LLINs (PermaNet Dual, n=12) or (2) PBO-pyrethroid LLINs (PermaNet 3.0, n=12).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
215903 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PermaNet Dual
Arm Type
Experimental
Arm Description
long lasting insecticidal nets with chlorfenapyr-pyrethroid
Arm Title
PermaNet 3.0
Arm Type
Active Comparator
Arm Description
long lasting insecticidal nets with PBO-pyrethroid
Intervention Type
Other
Intervention Name(s)
long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)
Intervention Description
Next-generation bed net combining insecticides with different modes of action
Intervention Type
Other
Intervention Name(s)
long lasting insecticidal nets with PBO-pyrethroid (PermaNet)
Intervention Description
Next-generation bed net combining an insecticide with a synergist
Intervention Type
Behavioral
Intervention Name(s)
Social Behavior Change Communication
Intervention Description
The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
Primary Outcome Measure Information:
Title
Number of cases of laboratory-confirmed malaria diagnosed at the MRC among patients residing in the target area
Description
malaria incidence: number of cases divided by the total population of the target area
Time Frame
24-months follow up
Secondary Outcome Measure Information:
Title
Prevalence of parasitaemia
Description
Proportion of blood smears positive for parasites by microscopy in individuals of all ages at the time of cross-sectional surveys
Time Frame
24-months following LLIN distribution
Title
Prevalence of anemia
Description
Proportion of children aged 2-4 years with haemoglobin < 11 g/dL at the time of cross-sectional surveys
Time Frame
24-months following LLIN distribution
Title
Proportion of households that owned at least one LLIN
Description
Proportion of households with at least one LLIN at the time of cross-sectional surveys
Time Frame
24-months following LLIN distribution
Title
Proportion of households that owned at least one LLIN for every two occupants
Description
Proportion of households with at least one LLIN per every two occupants at the time of cross-sectional surveys
Time Frame
24-months following LLIN distribution
Title
Proportion of household residents who slept under an LLIN the previous night
Description
Proportion of households residents who report sleeping under LLIN the previous night at the time of cross-sectional surveys
Time Frame
24-months following LLIN distribution
Title
Number of female anopheles mosquitoes collected per household at the time of cross-sectional surveys
Description
Vector density
Time Frame
24-months following LLIN distribution

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Household Survey Inclusion Criteria: At least one adult aged 18 years or older present Adult is a usual resident who slept in the sampled household on the night before the survey Agreement of the adult resident to provide informed consent for the household and entomology survey Exclusion Criteria: Dwelling destroyed or not found Household vacant No adult resident home on more than 3 occasions Clinical Survey Inclusion Criteria: Usual resident who was present in the sampled household on the night before the survey Agreement of adult or parent/guardian (of children) to provide informed consent Agreement of child aged 8 years or older to provide assent Exclusion Criteria: 1. Resident not home on day of survey
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Grant Dorsey, MD, PhD
Phone
628-206-4680
Email
grant.dorsey@ucsf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Tamara Clark, MHS
Phone
628-206-8790
Email
tamara.clark@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Moses Kamya, MBChB, MMed, PhD
Organizational Affiliation
Makerere University; Infectious Diseases Research Collaboration
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Grant Dorsey, MD, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Infectious Diseases Research Collaboration
City
Kampala
Country
Uganda
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Moses Kamaya, MBChB, MPH, PhD
Email
mkamya@infocom.co.ug
First Name & Middle Initial & Last Name & Degree
Moses Kamya, BChB, MPH, PhD
First Name & Middle Initial & Last Name & Degree
Samuel Gonahasa, MBChB, MSc
First Name & Middle Initial & Last Name & Degree
Joaniter Nankabirwa, MSc, PhD
First Name & Middle Initial & Last Name & Degree
Catherine Maiteki-Sebuguzi, MBChB, MSc
First Name & Middle Initial & Last Name & Degree
Henry Mawejje, BSc, MSc, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

LLIN Evaluation in Uganda Project (LLINEUP3)

We'll reach out to this number within 24 hrs